Valuation: Sirnaomics Ltd.

Market Cap 57.33M 450M 51.34M 47.23M 42.79M 79.99M 5.44B 81.49M 563M 226M 2.86B 215M 211M 9.03B P/E 2024
-0.67x
P/E 2025 -6.46x
Enterprise Value 53.12M 417M 47.58M 43.76M 39.65M 74.12M 5.04B 75.51M 522M 210M 2.65B 199M 195M 8.37B EV / Sales 2024
24.1x
EV / Sales 2025 -
Free-Float
73.19%
Yield 2024 *
-
Yield 2025 -
1 week+3.25%
Current month+8.68%
1 month+8.68%
3 months+5.09%
6 months-35.47%
Current year-46.15%
1 week 3.82
Extreme 3.82
4.2
1 month 3.6
Extreme 3.6
4.2
Current year 3.55
Extreme 3.55
10.72
1 year 3.55
Extreme 3.55
10.72
3 years 2.35
Extreme 2.35
48.95
5 years 2.35
Extreme 2.35
101
10 years 2.35
Extreme 2.35
101
Manager TitleAgeSince
Chief Executive Officer 48 06/11/2024
Director of Finance/CFO 58 01/10/2025
Director of Finance/CFO 35 01/09/2021
Director TitleAgeSince
Chairman 48 01/12/2025
Director/Board Member 56 17/02/2025
Director/Board Member 50 03/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
30/03/26 Other 38,000 0.0354%
24/11/24 Other

Chief Executive Officer

12,067 0.0138%
05/06/24 Other

Executive/Senior Manager

5,000 0.0057%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.25%-57.02%-91.47% 57.33M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.31%+7.11%+37.37%+176.54% 39.44B
Weighted average by Cap. +0.18%+5.44%+48.49%+186.09%

Financials

2024 2025
Net sales 1.78M 13.95M 1.59M 1.46M 1.33M 2.48M 169M 2.53M 17.47M 7.01M 88.81M 6.67M 6.53M 280M -
Net income -51.38M -403M -46.02M -42.33M -38.35M -71.69M -4.88B -73.04M -505M -203M -2.57B -193M -189M -8.09B -14.4M -113M -12.9M -11.87M -10.75M -20.1M -1.37B -20.47M -141M -56.8M -719M -54.05M -52.9M -2.27B
Net Debt -3.71M -29.11M -3.32M -3.06M -2.77M -5.18M -352M -5.27M -36.46M -14.64M -185M -13.93M -13.63M -585M -4.2M -32.98M -3.77M -3.46M -3.14M -5.87M -399M -5.98M -41.3M -16.58M -210M -15.78M -15.44M -662M
Projected Income Statement - Annual - Sirnaomics Ltd.
Logo Sirnaomics Ltd.
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a multi-targeted siRNA therapeutic advancing clinical development across two oncology indications: squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Its STP707 is an intravenous siRNA therapeutic being evaluated in phase I clinical trial for multiple solid tumors, including colorectal, pancreatic, liver, and metastatic melanoma cancers. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
Employees
-
Date Price Change Volume
30/10/26 HK$4.130 0.00% 12,500
29/10/26 HK$4.130 +5.22% 4,700
28/10/26 HK$3.925 -6.44% 8,300
27/10/26 HK$4.195 +1.82% 24,150
26/10/26 HK$4.120 +3.00% 69,250
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5264USD
Average target price
9.200USD
Spread / Average Target
+1,647.60%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Sirnaomics Ltd.
  1. Stock Market
  2. Stocks
  3. 2257 Stock